Quantification of ligand and mutation-induced bias in EGFR phosphorylation in direct response to ligand binding

Abstract

The 58 receptor tyrosine kinases (RTKs) are critically important for human development, and are implicated in many growth disorders and cancers. Here we introduce a methodology to identify and quantify bias in RTK signal transduction across the plasma membrane, and to quantify phosphorylation efficiencies, without contributions from feedback loops and system bias. We show that RTK biased signaling can occur in the first step of signal transduction not only in response to different ligands, but as a consequence of RTK pathogenic mutations as well. Ligand bias and mutation-induced bias are uncoupled here based on a comprehensive data set of dose response curves acquired for three ligands, EGF, TGF and epiregulin, for wild-type EGFR and for the oncogenic L834R EGFR mutant found in patients with non-small-cell lung cancer (NSCLC). Ligand bias has been extensively studied for GPCRs, and has revolutionized the GPCR field. The demonstration of pathogenic mutation-induced bias in RTK signal transduction across the plasma membrane will open new avenues for the exploration of RTK biased inhibitors as highly specific anti-cancer therapies.